ERDAFIXEN 4 mg (Erdafitinib): Uses, Dosage & Side Effects
ERDAFIXEN 4 mg (Erdafitinib): Uses, Dosage, Side Effects & FGFR3-Positive Bladder Cancer
WHAT IS ERDAFIXEN 4 mg?
ERDAFIXEN 4 mg contains erdafitinib, a targeted cancer medicine that inhibits FGFR signalling.
Fibroblast growth factor receptors are proteins involved in cellular communication. They help regulate processes such as cell growth, survival, differentiation and blood-vessel development. Genetic alterations affecting FGFR3 can cause abnormal signalling that contributes to cancer-cell growth.
Erdafitinib is designed to interfere with this abnormal signalling. It belongs to the FGFR tyrosine kinase inhibitor family and acts on FGFR1, FGFR2, FGFR3 and FGFR4.
The medicine has an important role in selected patients with advanced urothelial cancer whose tumours contain susceptible FGFR3 alterations.
Importantly, treatment selection is not based simply on having bladder cancer. Appropriate molecular testing is required to identify patients whose tumours have the relevant genetic alteration. The U.S. prescribing information specifically recommends selection using an FDA-approved companion diagnostic.
WHAT IS ERDAFIXEN 4 mg USED FOR?
Erdafitinib is used for certain adults with locally advanced or metastatic urothelial carcinoma containing susceptible FGFR3 genetic alterations.
Current U.S. information describes use in patients whose disease has progressed during or after at least one prior systemic treatment, while the current European indication specifies prior therapy containing a PD-1 or PD-L1 inhibitor in the unresectable or metastatic setting.
Patient-Friendly Explanation
Urothelial carcinoma is a cancer that develops in the tissues lining the urinary system, most commonly the bladder.
Some urothelial cancers contain specific changes in the FGFR3 gene. These changes can activate signalling pathways that encourage cancer cells to grow.
Erdafitinib is intended for patients whose tumours have an eligible FGFR3 alteration.
Medical Explanation
Erdafitinib inhibits FGFR tyrosine kinase activity and thereby interferes with downstream signalling associated with cellular proliferation and survival.
Because the treatment is molecularly targeted, confirmation of a susceptible FGFR3 alteration is an important component of patient selection.
KEY INDICATIONS
Erdafitinib may be considered for appropriately selected adults with:
- Locally advanced urothelial carcinoma
- Metastatic urothelial carcinoma
- Urothelial cancer containing susceptible FGFR3 genetic alterations
- Disease that has progressed following prior systemic treatment, according to the applicable regulatory indication
- Patients meeting the required previous-treatment criteria
The exact approved indication can vary between countries, so the local prescribing information should always be followed.
HOW DOES ERDAFITINIB WORK?
Erdafitinib works by targeting fibroblast growth factor receptors (FGFRs).
FGFR proteins are receptor tyrosine kinases located on the cell surface. When activated by fibroblast growth factors, they transmit signals into the cell.
These signals can influence:
- Cell proliferation
- Cell survival
- Cellular differentiation
- Tumour development
- Angiogenic processes
In some urothelial cancers, genetic alterations involving FGFR3 can cause excessive or abnormal receptor signalling.
A simplified biological pathway is:
FGFR3 genetic alteration → abnormal FGFR signalling → downstream growth signals → tumour-cell proliferation
Erdafitinib acts further upstream:
Erdafitinib → FGFR inhibition → reduced abnormal signalling → interference with tumour-cell growth and survival
Erdafitinib is therefore considered a targeted molecular therapy, rather than conventional cytotoxic chemotherapy.
Its therapeutic effect depends on the tumour having an appropriate molecular target. This is why genetic testing is important before treatment.
ERDAFIXEN 4 mg DOSAGE & ADMINISTRATION
The recommended starting dose of erdafitinib is 8 mg once daily, not 4 mg once daily.
The FDA prescribing information states that treatment starts at 8 mg once daily, with a possible increase to 9 mg once daily after 14–21 days depending on tolerability and serum phosphate levels.
Therefore, the 4 mg strength is a tablet strength used in dose adjustment, rather than the standard starting dose.
Administration
- Take erdafitinib once daily as prescribed.
- Tablets may be taken with or without food.
- Swallow tablets whole.
- Take the medicine at approximately the same time each day.
- Do not alter the prescribed dose without medical advice.
- Treatment generally continues until disease progression or unacceptable toxicity, according to the prescribing information.
Missed Dose
If a dose is missed, the FDA prescribing information states that it may be taken as soon as possible on the same day, followed by the regular daily schedule the next day. Patients should not take extra tablets to compensate.
COMMON SIDE EFFECTS
Reported adverse reactions with erdafitinib include:
- Increased phosphate levels
- Nail disorders
- Stomatitis
- Diarrhea
- Increased creatinine
- Fatigue
- Dry mouth
- Dry skin
- Reduced appetite
- Taste changes
- Constipation
- Hair loss
- Hand-foot syndrome
- Dry eye
- Eye-related disorders
The U.S. prescribing information lists increased phosphate, nail disorders, stomatitis, diarrhea and other laboratory or clinical abnormalities among commonly observed reactions.
SERIOUS SIDE EFFECTS
Important potential adverse effects include:
Eye Disorders
Erdafitinib can cause central serous retinopathy/retinal pigment epithelial detachment (CSR/RPED), which can affect vision.
Regular ophthalmologic monitoring is recommended during treatment.
Hyperphosphatemia
Increased blood phosphate is a pharmacological effect of erdafitinib. Serum phosphate should be monitored and managed when necessary.
Other Clinically Important Effects
Patients may also experience:
- Severe skin or nail reactions
- Significant diarrhea
- Severe mouth inflammation
- Kidney-related laboratory abnormalities
- Electrolyte abnormalities
- Severe ocular symptoms
WHEN TO SEEK MEDICAL ATTENTION
Promptly contact a healthcare professional if you experience:
- New or worsening blurred vision
- Visual field changes
- Difficulty seeing clearly
- Significant eye discomfort
- Severe diarrhea
- Severe mouth inflammation
- Severe skin or nail problems
- Marked weakness or dehydration
- Symptoms that become severe or rapidly worsen
Any new visual disturbance during treatment deserves particular attention because of the known ocular risks associated with erdafitinib.
DRUG INTERACTIONS
Erdafitinib can interact with other medicines.
Medicines Requiring Caution
The U.S. prescribing information identifies potential interactions involving:
- Moderate CYP2C9 inhibitors
- Strong CYP3A4 inhibitors
- Strong CYP3A4 inducers
- Moderate CYP3A4 inducers
- Medicines that alter serum phosphate
- Certain P-glycoprotein (P-gp) substrates
Strong CYP3A4 inducers should be avoided, while other interacting medicines may require alternative treatment, monitoring or dose adjustment.
Supplement Considerations
Tell the healthcare team about:
- Vitamins
- Herbal products
- Mineral supplements
- Traditional medicines
- Over-the-counter medicines
Do not start a new supplement without professional advice.
WARNINGS & PRECAUTIONS
Eye Monitoring
Ophthalmologic monitoring is an important part of erdafitinib treatment.
The U.S. prescribing information recommends monthly eye examinations during the first four months, followed by examinations every three months and additional evaluation whenever visual symptoms occur.
Phosphate Monitoring
Serum phosphate should be assessed before treatment and monitored during therapy. Increased phosphate can require dietary, medical or dose-management measures.
Kidney Considerations
Changes in creatinine and protein-related laboratory abnormalities can occur, so renal status may need clinical monitoring.
Skin, Nail and Mouth Reactions
Skin dryness, nail changes, stomatitis and hand-foot syndrome can occur and may require supportive management.
PREGNANCY & BREASTFEEDING
Erdafitinib can cause fetal harm. Patients who can become pregnant should discuss effective contraception with their healthcare professional before and during treatment.
The medicine is not recommended during breastfeeding. Patients should discuss breastfeeding plans with their healthcare professional before starting treatment.
SPECIAL POPULATIONS
Elderly Patients
Erdafitinib may be used in older adults when clinically appropriate. Treatment decisions should consider overall health, concurrent medicines and tolerance.
Pediatric Patients
Erdafitinib is not an established routine treatment for pediatric urothelial carcinoma under the current approved indication.
Renal Impairment
Patients with kidney impairment should inform their oncology team before treatment. Individual renal status should be considered during monitoring.
Hepatic Impairment
Patients with liver disease should discuss their condition with their healthcare professional before treatment. Clinical assessment may influence treatment and monitoring.
STORAGE
Store ERDAFIXEN according to the product-specific storage instructions provided with the packaging.
General precautions:
- Keep tablets in their original packaging.
- Keep out of reach of children.
- Protect from unsuitable heat and moisture.
- Do not use expired tablets.
- Do not use damaged tablets.
- Follow the storage conditions stated on the product label.
FREQUENTLY ASKED QUESTIONS
1. What is ERDAFIXEN 4 mg used for?
ERDAFIXEN contains erdafitinib, a targeted FGFR inhibitor used for appropriately selected adults with advanced or metastatic urothelial carcinoma containing susceptible FGFR3 alterations.
2. What is Erdafitinib?
Erdafitinib is an oral FGFR tyrosine kinase inhibitor used in selected patients with FGFR3-altered urothelial cancer.
3. Is Erdafitinib a chemotherapy medicine?
Erdafitinib is a targeted kinase inhibitor rather than conventional cytotoxic chemotherapy.
4. How does Erdafitinib work?
It inhibits FGFR signalling, interfering with molecular pathways involved in cancer-cell growth and survival.
5. What is the standard starting dose of Erdafitinib?
The current U.S. prescribing information recommends an initial dose of 8 mg once daily, with possible escalation to 9 mg based on tolerability and phosphate levels.
6. Is 4 mg the normal starting dose?
No. The 4 mg tablet is one available strength and can be used as part of dose adjustment. The standard U.S. starting regimen is 8 mg once daily.
7. Does Erdafitinib treat bladder cancer?
It is used for selected patients with locally advanced or metastatic urothelial carcinoma containing susceptible FGFR3 genetic alterations.
8. Is FGFR3 testing necessary?
Appropriate molecular testing is required to identify patients with susceptible FGFR3 alterations before treatment.
9. What are common Erdafitinib side effects?
Commonly reported effects include increased phosphate, nail disorders, stomatitis, diarrhea, fatigue, dry skin, dry mouth and appetite changes.
10. Can Erdafitinib affect vision?
Yes. Erdafitinib can cause serious ocular disorders, including central serous retinopathy/retinal pigment epithelial detachment.
11. Why are phosphate levels monitored?
Increased serum phosphate is a pharmacodynamic effect of FGFR inhibition and can require monitoring and treatment adjustment.
12. Can Erdafitinib be taken with food?
Yes. The U.S. prescribing information states that erdafitinib tablets can be swallowed whole with or without food.
13. Can Erdafitinib be used during pregnancy?
Erdafitinib may harm a developing fetus and should only be used during pregnancy when specifically determined appropriate by the treating medical team.
14. Can Erdafitinib be used while breastfeeding?
Breastfeeding is not recommended during treatment according to current U.S. prescribing information.
15. Is Erdafitinib a prescription medicine?
Yes. Erdafitinib is a prescription oncology medicine requiring specialist medical supervision.
GLOBAL MEDICINE INFORMATION & SUPPORT BY ROOTAID PHARMA
Global Medicine Information & Support by RootAid Pharma
RootAid Pharma provides educational information and international support resources relating to prescription and specialty medicines.
Our information resources cover areas such as:
- Oncology medicines
- Urothelial cancer treatments
- Targeted cancer therapies
- FGFR-targeted medicines
- Specialty medicines
- Prescription medicine information
- International medicine information
- Treatment-related educational resources
For medicines such as erdafitinib, appropriate molecular testing and specialist assessment are important before treatment.
RootAid Pharma does not claim to manufacture ERDAFIXEN or erdafitinib. Medicine availability, prescription requirements, import regulations and supply conditions may vary between countries.
MEDICAL DISCLAIMER
This content is provided for general educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, treatment planning or official prescribing information.
Erdafitinib is a prescription anticancer medicine that should be used only in patients meeting the applicable clinical and molecular criteria. Treatment selection, genetic testing, dosage, monitoring, dose modifications and treatment duration should be determined by a qualified healthcare professional.
Approved indications and prescribing requirements can differ between countries. Always consult the official product information applicable to your location and follow the instructions of your treating healthcare professional.
Do not start, stop or change erdafitinib treatment without medical supervision.
Medical information verified against current FDA/DailyMed and EMA regulatory information.
Need help after reading this?
Talk to our support team for sourcing guidance, product availability, and global delivery assistance.